Is Mochi Health Legit? What the Lawsuit, Aequita Shutdown, and BBB Records Show

Is Mochi Health a real company, or a scam?

Mochi Health is a real, operating telehealth company — not a storefront that takes your card number and disappears. It's incorporated as Mochi Health Corp., headquartered in San Francisco, and was founded in 2022 by physician Myra Ahmad. The company says it has served more than 500,000 patients through a network of ABOM-certified physicians licensed across all 50 states, and prescriptions are written by real clinicians and dispensed through a network of partner compounding pharmacies rather than manufactured in-house.

None of that means the company is free of legal or regulatory friction, and a scary headline about a lawsuit or a pharmacy shutdown doesn't automatically mean the opposite either. Mochi is a named defendant in an ongoing Eli Lilly lawsuit, one of its former pharmacy partners was shut down by a state regulator for sterile-compounding violations, and it operates in a corner of the drug industry — compounded GLP-1s — that the FDA is actively trying to narrow. Here's what each of those actually means, with links to the primary records.

Has Mochi Health been sued? The Eli Lilly lawsuit, explained

Yes. On April 23, 2025, Eli Lilly and Company filed a federal lawsuit in the U.S. District Court for the Northern District of California naming Mochi Health Corp., its clinical entities Mochi Medical CA P.C. and Mochi Medical P.A., and its then-pharmacy partner Aequita as defendants — case No. 3:25-cv-03534. The same week, Lilly filed nearly identical suits against Henry Meds, Willow Health, and Fella Health/Delilah, part of a coordinated legal push against telehealth companies selling compounded versions of its GLP-1 drugs.

Lilly's allegations are about marketing language, not product safety: that Mochi misrepresented its compounded tirzepatide as "personalized," implied the medication was as safe and effective as Lilly's FDA-approved Zepbound based on studies conducted on Lilly's own product, and in some instances suggested the compounded version was itself FDA-approved. Lilly also argues that Mochi's corporate structure — hiring and directing the physicians at its affiliated medical practices — makes it legally responsible for what those practices advertise. This is a civil unfair-competition and trademark dispute between a drugmaker and a compounding-based competitor, not a criminal case, an FDA enforcement action, or a patient lawsuit over harm.

What's the lawsuit's status now, in mid-2026?

Moving, not resolved. A federal judge dismissed Lilly's original complaint in October 2025 for not alleging specific enough harm, but allowed Lilly to refile. The amended complaint fared better: at an April 9, 2026 hearing, Judge Jacqueline Scott Corley allowed Lilly's claims under California's Unfair Competition Law and the federal Lanham Act to proceed, while dismissing a broader civil-conspiracy claim with permission to amend. Lilly filed a Second Amended Complaint by the court's May 8, 2026 deadline, and on June 18, 2026, Mochi Health and a pharmacy co-defendant filed a targeted motion to dismiss the conspiracy claim in that amended version.

As of this writing, that motion is pending. There's been no ruling on it, no settlement, no trial, and no finding that Mochi committed fraud. The claims that have survived so far concern marketing language and unfair competition — the same narrow category Lilly is pursuing against Henry Meds and the other named telehealth companies. Check the live docket on CourtListener for the current status before relying on any single article's summary, including this one.

Is Mochi Health safe? What happened with the Aequita pharmacy shutdown

This is the most concrete safety concern in Mochi's history, and it deserves real weight rather than a passing mention. Aequita Pharmacy, a Kirkland, Washington compounding facility that was one of Mochi's primary suppliers, was hit with a Limited Stop Service order from Washington's Pharmacy Quality Assurance Commission on March 13, 2025, followed by a Notice of Immediate Jeopardy. State inspectors and whistleblowers described untrained temporary workers, some recruited in hardware-store parking lots, handling sterile compounding without proper supervision, cheap vials sourced overseas, frozen snack-food ice packs standing in for medical-grade cold packs, and vials still awaiting shipment months past their expiration date.

Aequita stopped compounding operations around April 2025, and Mochi patients who relied on it experienced real shipping delays during the transition. The pharmacy and Washington's pharmacy board reached an agreed order in July 2025 requiring ongoing compliance monitoring, quarterly reporting, and staff retraining before Aequita could resume any sterile compounding at all. Mochi has since diversified its supply chain: by its own account, the company expanded from roughly 10 to 33 partner pharmacies in a single quarter in late 2025, with a stated goal of exceeding 100 partners going forward — a direct response to routing too much volume through one facility. That diversification is a reasonable structural fix, but it doesn't undo what already happened, and it's worth asking your own provider which specific pharmacy is filling your prescription and whether that facility's state license is current and unrestricted.

Has the FDA taken action against Mochi Health?

No brand-specific warning letter to Mochi Health or joinmochi.com turns up in FDA's public warning-letter database as of this writing. In March 2026, the FDA sent a second wave of warning letters to 30 telehealth companies over marketing that implied compounded GLP-1 products were equivalent to FDA-approved drugs; Mochi does not appear among the companies named in that announcement. That's a meaningfully different posture than the operators the FDA singled out, but the absence of a letter isn't a safety clearance, and Mochi's compounded semaglutide and tirzepatide remain unapproved compounded products regardless of warning-letter status.

The more relevant regulatory development is structural rather than punitive. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, concluding that the drug shortages which originally justified large-scale compounding have resolved. That's a proposal, not a final rule, and it targets 503B outsourcing facilities specifically rather than the 503A patient-specific pharmacies most of Mochi's network relies on. The comment period, originally set to close June 29, 2026, was extended to July 30, 2026, so there's still no final decision as of this writing — worth checking the Federal Register directly for whatever's happened since.

What's Mochi Health's BBB rating, and what does Trustpilot say?

These two sources disagree in tone, and both are worth reading. Mochi Health's current BBB profile, listed under the company's San Francisco address, shows a B- rating, no BBB accreditation, and 1,359 complaints on file, with BBB describing the recurring themes as cancellation and refund disputes. You may see the rating cited elsewhere as an F or a plain B — both are outdated snapshots of a profile that moves as new complaints and responses are logged, so check bbb.org directly rather than trusting a third-party summary, including this one.

On Trustpilot, Mochi holds an "Excellent" rating in the 4.4-to-4.5-out-of-5 range across more than 15,000 reviews. Positive reviews consistently cite physician quality, flat-rate pricing, and shipping speed; negative reviews cluster around the same billing and cancellation friction BBB describes. That gap — a strong self-selected review average sitting next to a sizable complaint volume on a dispute-resolution platform — is common across direct-to-consumer telehealth generally, not unique to Mochi, but it's real here and worth reading before you hand over a card number.

What are people actually complaining about?

The dominant, recurring complaint across Reddit, BBB, and consumer-review sites is Mochi's two-part subscription structure. Membership and medication bill and cancel on separate cycles, and a meaningful share of complaints come from patients who canceled one and assumed both were stopped, only to be charged again the next month. Mochi's refund window is narrow — roughly 24 hours from payment, and nothing once medication has shipped — which compounds the frustration for anyone who cancels a day or two late. Shipping delays tied to the Aequita transition show up repeatedly in older complaints, though they read as less common in ones filed since mid-2025.

Treat this as a general characterization of sentiment rather than a citation of specific threads — this page hasn't done a first-hand sweep of individual Reddit posts. If you search it yourself before enrolling, weight detailed complaints with dates and specifics more heavily than a one-line "stay away" post, and keep in mind that a subscription-cancellation dispute is a different category of problem than a safety or fraud claim, even when it's genuinely frustrating to live through.

Red flags to check yourself before you pay

• Ask which of Mochi's 33+ partner pharmacies is filling your specific prescription, and confirm that pharmacy's state license is current and unrestricted — the single most concrete legitimacy check available to you as a patient.
• Read the cancellation flow before you enter a card number. Membership and medication are two separate subscriptions that must each be canceled on their own; canceling one does not cancel the other.
• Don't rely on a single review source. BBB's B- rating and complaint count and Trustpilot's "Excellent" average both describe the same company — reading only one gives you a distorted picture.
• Understand what the Eli Lilly lawsuit is and isn't. It's a marketing-language and unfair-competition dispute between competitors, still pending on narrowed claims — not a finding of fraud, not an FDA enforcement action, and not evidence the medication itself is unsafe.
• Track the FDA's proposed 503B exclusion. It's still a proposal as of this writing, not a final rule, but if finalized it could affect the compounded-GLP-1 supply chain that Mochi and its competitors depend on.
• Check current pricing and terms directly at joinmochi.com rather than trusting any third-party site's numbers, including this one — compounded GLP-1 pricing shifts industry-wide.

The bottom line: is Mochi Health legit?

Mochi Health is legitimate in the sense that matters most: it's a real, licensed company with real physicians, seeing real patients, dispensing real medication through pharmacies subject to real state oversight. It is also, right now, a defendant in an active lawsuit over marketing language, sitting on a BBB profile weighed down by billing complaints, and running a compounded-GLP-1 business the FDA is actively trying to narrow. None of that adds up to fraud, and none of it should be the only thing you read before deciding. But it's also not nothing — the Aequita shutdown in particular showed what can go wrong when a single pharmacy handles too much volume with too little oversight, which is exactly why asking your own provider which pharmacy fills your prescription is worth the two minutes it takes.